KU-55933 is an ATM inhibitor, which blocks the phosphorylation of Akt induced by insulin and insulin-like growth factor I in cancer cells that exhibit abnormal Akt activity. Moreover, KU-55933 inhibits cancer cell proliferation by inducing G(1) cell cycle arrest. It does so through the downregulation of the synthesis of cyclin D1, a protein known to be elevated in a variety of tumors. In addition, KU-55933 treatment during serum starvation triggers apoptosis in these cancer cells. Research results suggest that KU-55933 may be a novel chemotherapeutic agent targeting cancer resistant to traditional chemotherapy or immunotherapy due to aberrant activation of Akt. Furthermore, KU-55933 completely abrogates rapamycin-induced feedback activation of Akt. Combination of KU-55933 and rapamycin not only induces apoptosis, which is not seen in cancer cells treated only with rapamycin, but also shows better efficacy in inhibiting cancer cell proliferation than each drug alone. For detail see: http://www.ncbi.nlm.nih.gov/pubmed/20053781.
MedKoo Cat#: 201681
Name: KU-55933
CAS#: 587871-26-9
Chemical Formula: C21H17NO3S2
Exact Mass: 395.0650
Molecular Weight: 395.49
Elemental Analysis: C, 63.77; H, 4.33; N, 3.54; O, 12.14; S, 16.22
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 42.1 | 106.55 | |
| DMF | 30.0 | 75.86 | |
| DMF:PBS (pH 7.2) (1:1) | 0.5 | 1.26 | |
| Ethanol | 14.9 | 37.65 |
The following data is based on the product molecular weight 395.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
